UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
April 6, 2020
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Sydmarken 11
2860 Søborg (Copenhagen)
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-Fx Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Furnished as Exhibit 3.1 to this Report on Form 6-K are the updated Articles of Association of Zealand Pharma A/S, or the Company. TheArticles of Association have been amended to reflect changes approved during Zealand Pharma’s Annual General Meeting 2020.
Furnished as Exhibit 99.1 is thepress release (“company announcement”) of Zealand Pharma A/S, dated April 3, 2020, announcing the results of the Annual General Meeting that was held on April 2, 2020. Furnished as Exhibit 99.2 is the presentation from the Annual General Meeting 2020.
Exhibits
Reference is made to the Exhibit Index included hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Zealand Pharma A/S |
| | | |
| | By: | /s/ Matthew Dallas |
| | | Name: | Matthew Dallas |
| | | Title: | Chief Financial Officer |
Date: April 6, 2020
EXHIBIT INDEX
